Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Downgraded by DZ Bank to “Strong Sell”

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was downgraded by equities researchers at DZ Bank from a “strong-buy” rating to a “strong sell” rating in a research report issued on Wednesday,Zacks.com reports.

BAYRY has been the subject of a number of other research reports. JPMorgan Chase & Co. raised shares of Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a report on Monday, December 8th. Morgan Stanley upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, December 3rd. Zacks Research raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 20th. Finally, Barclays raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Tuesday, January 6th. Three analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy”.

Bayer Aktiengesellschaft Trading Down 7.6%

Shares of OTCMKTS:BAYRY opened at $13.31 on Wednesday. The company has a current ratio of 1.14, a quick ratio of 0.71 and a debt-to-equity ratio of 1.10. Bayer Aktiengesellschaft has a 12-month low of $5.30 and a 12-month high of $14.85. The business has a 50 day moving average of $12.08 and a two-hundred day moving average of $9.56. The company has a market capitalization of $52.31 billion, a PE ratio of -147.87, a PEG ratio of 5.17 and a beta of 0.68.

Trending Headlines about Bayer Aktiengesellschaft

Here are the key news stories impacting Bayer Aktiengesellschaft this week:

• Positive Sentiment: Bayer says the U.S. executive order invoking the Defense Production Act to secure domestic glyphosate supply should not cause shortages in other countries — this eases concerns about global crop protection supply disruptions. Bayer: glyphosate shortages not expected outside the US after executive order
• Positive Sentiment: Clinical update: Bayer’s DARO‑DUB study for darolutamide in advanced prostate cancer advances real‑world evidence for a key oncology franchise — a longer‑term potential revenue support item. DARO-DUB Study Sets Up New Real-World Test
• Neutral Sentiment: Bayer CEO says the proposed U.S. class settlement complements Bayer’s Supreme Court appeal strategy — this could help legal closure but timing and court outcomes remain uncertain. CEO: settlement is important addition to Supreme Court case
• Neutral Sentiment: Explainer on Bayer’s proposed $7.25 billion Roundup settlement outlines how a nationwide deal could resolve current and future suits — it may reduce long‑term legal overhang if accepted, but terms and scope are still being negotiated. Explainer: Will Bayer’s proposed $7.25 billion Roundup deal bring legal closure?
• Negative Sentiment: Market and analyst skepticism: coverage highlights a larger reported potential payout (reports of a $10.5B push) and questions over whether a $7–10B program delivers full closure — investors are pricing in higher legal costs and uncertainty, pressuring the stock. Bayer to make $10.5 bln push to settle roundup cases
• Negative Sentiment: Investor reaction: multiple reports show shares falling after Bayer disclosed the preliminary settlement framework; BloombergLaw and other outlets cite skepticism about whether the proposed amounts and deal structure will fully eliminate future liabilities. Bayer’s $7 Billion Bid to End Roundup Curse Draws Skepticism

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.